Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Ryan M. Esquejo Clear advanced filters

  • UCN2 acts as a ligand for the GPCR CRHR2 and there have been conflicting reports on whether UCN2 treatment improves or worsens glucose tolerance. Here, the authors show that acute UCN2 recruits Gs and decreases glucose uptake, while chronic treatment desensitizes CRHR2 and improves glucose uptake.

    • Stephen E. Flaherty III
    • Olivier Bezy
    • Zhidan Wu
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-16

  • Results from a phase 1 study testing a new oral GLP-1 receptor agonist, danuglipron, in patients with type 2 diabetes demonstrate acceptable safety, tolerability and pharmacokinetic profiles of the drug, with exploratory analyses suggesting potential beneficial effects on glycemic control.

    • Aditi R. Saxena
    • Donal N. Gorman
    • Albert M. Kim
    Research
    Nature Medicine
    Volume: 27, P: 1079-1087

  • The hepatic enzyme FMO3 has been linked to atherosclerosis. Here the authors show that FMO3 is upregulated in various models of diabetes and link FMO3 with key transcriptional regulators of hepatic glucose and cholesterol synthesis, thus proposing a mechanistic connection between diabetes and atherosclerosis.

    • Ji Miao
    • Alisha V. Ling
    • Sudha B. Biddinger
    ResearchOpen Access
    Nature Communications
    Volume: 6, P: 1-10